DOI: http://dx.doi.org/10.18203/2349-3933.ijam20214131

Study of prognostic factors in multiple myeloma

Geeta Rathnakumar, Kinjalka Ghosh, Nikhil Choudhary, Narendra Kamble, Nitin Inamdar

Abstract


Background: Multiple myeloma (MM) is cancer of the plasma cell characterized by interpatient heterogeneity, in most of the cases it is incurable. It is the second most common hematological malignancy. Overall survival of patients has significantly increased recently. Lot of research is going on for prognostic factors, which can predict disease and response to therapy. During the past decades, biomarkers: M protein and β2 microglobulin have shaped the knowledge about MM. This study was undertaken to evaluate the role of prognostic factors in newly diagnosed and few follow up patients of MM before, during and after the treatment in Indian population.

Methods: We analyzed 177 samples (90 MM patients and 87 healthy control) for creatinine, calcium, phosphorus, LDH, total protein, albumin, globulin, β2M, Immunoglobulines (Igs), IgG, IgA, IgM, Kappa light chain and Lambda light chains, serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE).

Results: The result of our study are significant at p<0.0001 for creatinine, β2M, LDH, albumin, globulin and immunoglobulins whereas for calcium and phosphorus results are not significant at p<0.005. We observed that the levels of β2m, creatinine, LDH and M band concentration declined during the treatment (chemotherapy).

Conclusions: We conclude that these results will help the clinicians to tailor-made the chemotherapy doses for betterment of patients and improve survival rate in MM patients.


Keywords


Multiple myeloma, β2 microglobulin, LDH, Calcium, Immunoglobulins, SPE and IFE

Full Text:

PDF

References


Rajkumar SV, Kumar S. Multiple Myeloma Diagnosis and Treatment. Mayo Clin Proce. 2016;91:101-19.

Alexanian R, Weber D, Liu F. Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med. 1999;123:108-113.

Durie BGM, Salmon SE. Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In: Hoffbrand AV, Brain MC, Hirsch J, eds. Recent advances in hematology. Edinburgh: Churchill Livingstone. 1977:243–61.

Understand the Immune system: U.S. department of health and human services national institutes of health: National Institute of Allergy and Infectious Diseases NIH Publication No. 03-5423;September 2003: National Cancer Institute.

SEER Stat Fact Sheets: Myeloma. NCI Surveillance, Epidemiology, and End Results Program. Accessed on 18 August 2016.

Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ et al. SEER Cancer Statistics Review, 1975–2003, National Cancer Institute. Bethesda, MD, 2006. Available at: http://seer.cancer.gov/csr/1975_2003. Accessed on 30 April 2008.

Kyle RA, Child JA, Anderson K, Barlogie B, Bataille R, Bensinger W et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 2003;121(5):749-57.

Hayflick S, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585-621.

Avilés A, Zepeda G, Guzmán R, Talavera A, García EL, Díaz-Maqueo JC. Prognostic importance of beta-2-microglobulin in multiple myeloma. Rev Invest Clin. 1992;44(2):215-20.

Chelazzi G, Senaldi G. Serum beta 2-microglobulin levels in multiple myeloma and monoclonal gammapathy of undetermined significance: a clinical study of 55 patients. Ric Clin Lab. 1986;16(1):53-8.

The American Cancer Society medical and editorial content team. Available at. Accessed on 19 January 2016.

Available at: https://www.themmrf.org. Accessed on 19 January 2016.

Hutchison CA, Batuman V, Behrens J, Bridoux F, Sirac C, Dispenzieri A, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nature reviews Nephrology. 2012;8(1):43-51.

Kim JE1, Yoo C, Lee DH, Kim SW, Lee JS, Suh C. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol. 2010;89(4):391-7.

Mani R, Murthy SS, Jamil K. Role of Serum Lactate Dehydrogenase as a Bio-Marker in Therapy Related Hematological Malignancies. International Journal of Cancer Research. 2006;2:383-9.

MedCalc Software bvba [BE]. Available at: https://www.medcalc.org/manual/roc-curves.php. Accessed on 19 January 2016.

Choo-Kang E, Campbell M. Biochemical abnormalities in multiple myeloma. West Indian Med J. 1991;40(4):170-2.

Defronzo RA, Humphrey RL, Wright JR, Cooke CR. Acute renal failure in multiple myeloma. Medicine (Baltimore) 1975;54(3):209-23.

DeFronzo RA, Cooke CR, Wright JR, Humphrey RL. Renal function in patients with multiple myeloma. Medicine (Baltimore). 1978;57(2):151-66.

Prakash J, Niwas SS, Parekh A, Vohra R, Wani IA, Sharma N et al. Multiple myeloma--presenting as acute kidney injury. J Assoc Physicians India. 2009;57:23-6.

Michels TC, Petersen KE. Multiple Myeloma: Diagnosis and Treatment. Am Fam Physician. 2017;95(6):373-83.

Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol. 2006;17:2533-45.

Nasr SH, Valeri AM, Sethi S. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies., et al. Am J Kidney Dis. 2012;59:786-94.

Prakash J, Mandal AK, Vohra R, Wani IA, Hota JK, Raja R et al. Renal disease is a prodrome of multiple myeloma: an analysis of 50 patients from eastern India. 2009;31:267-71.

Goldschmidt H, Lannert H, Bommer J, Ho AD. Multiple myeloma and renal failure. Nephrol Dial Transplant. 2000;15(3):301-4.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-48.

Abbott KC, Agodoa LY. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephron. 2001;56:207-10.

Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, Parcharidou A et al. Greek Myeloma Study Group, Greece.; High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol. 2010;85(2):114-9.

Patel KK, Orlowski RZ, Weber DM, Wang M, Thomas SK, Shah JJ et al. Prognostic value of serum lactate dehydrogenase in symptomatic multiple myeloma. J Clin Oncol; 30: 2012

Teke HU, Başak M, Teke D, Kanbay M. Serum levels of lactate dehydrogenase is a useful clinical marker to monitor progressive myeloma disease. Turk J Haematol. 2014;31(1):84-7.

Rossi D, Fangazio M, De Paoli L, Puma A, Riccomagno P, Pinto V et al. Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. Cancer 2010 May 1;116(9):2188-200.

Chelazzi G, Senaldi G. Serum beta 2-microglobulin levels in multiple myeloma and monoclonal gammapathy of undetermined significance: a clinical study of 55 patients. Ric Clin Lab. 1986;16(1):53-8.